GSK completes patient enrolment in new pulmonary disease study

GlaxoSmithKline (GSK) and Theravance have announced the completion of patient enrolment in the SUMMIT trial designed to determine the impact of Relvar/Breo Ellipta (fluticasone furoate'FF'/vilanterol 'VI') in patients with moderate chronic obstructiv…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news